Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors

Cancer Science

Volumn 105, Issue 5, 2014, Pages 528-536

  Yamaguchi, Hideki ^a   Takanashi, Miho ^a,b   Yoshida, Nachi ^a,b   Ito, Yuumi ^a,b   Kamata, Reiko ^a   Fukami, Kiyoko ^b   Yanagihara, Kazuyoshi ^a   Sakai, Ryuichi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

C Met; C src; Neoplasm metastasis; Saracatinib; Stomach neoplasms

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; CRIZOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 2; JNJ 38877605; PROTEIN TYROSINE KINASE INHIBITOR; SARACATINIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL GROWTH; DIFFUSE TYPE GASTRIC CARCINOMA CELL LINE; DRUG SENSITIVITY; GASTRIC CANCER CELL LINE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MASS SPECTROMETRY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; STOMACH CARCINOMA;

C-MET; C-SRC; NEOPLASM METASTASIS; SARACATINIB; STOMACH NEOPLASMS;

ANTINEOPLASTIC AGENTS; BENZODIOXOLES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; PERITONEUM; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STOMACH NEOPLASMS;

EID: 84899989631     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12387     Document Type: Article

References (40)

1. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
2. Jinawath N, Furukawa Y, Hasegawa S et al. Comparison of gene-expression profiles between diffuse- and intestinal-type gastric cancers using a genome-wide cDNA microarray. Oncogene 2004; 23: 6830-44.
3. Ming SC. Cellular and molecular pathology of gastric carcinoma and precursor lesions: a critical review. Gastric Cancer 1998; 1: 31-50.
4. Sipponen P. Gastric cancer: pathogenesis, risks, and prevention. J Gastroenterol 2002; 37 (Suppl 13): 39-44.
5. Yashiro M, Hirakawa K. Cancer-stromal interactions in scirrhous gastric carcinoma. Cancer Microenviron 2010; 3: 127-35.
6. Ikeguchi M, Miyake T, Matsunaga T et al. Recent results of therapy for scirrhous gastric cancer. Surg Today 2009; 39: 290-4.
7. Otsuji E, Kuriu Y, Okamoto K et al. Outcome of surgical treatment for patients with scirrhous carcinoma of the stomach. Am J Surg 2004; 188: 327-32.
8. Hattori Y, Itoh H, Uchino S et al. Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 1996; 2: 1373-81.
9. Hattori Y, Odagiri H, Nakatani H et al. K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. Proc Natl Acad Sci USA 1990; 87: 5983-7.
10. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 1992; 189: 227-32.
11. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834-48.
12. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7: 504-16.
13. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 2010; 46: 1260-70.
14. Liu X, Newton RC, Scherle PA. Development of c-MET pathway inhibitors. Expert Opin Investig Drugs 2011; 20: 1225-41.
15. Lee J, Seo JW, Jun HJ et al. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 2011; 25: 1517-24.
16. Toiyama Y, Yasuda H, Saigusa S et al. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer 2012; 130: 2912-21.
17. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10: 116-29.
18. Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013; 3: 264-79.
19. Kawakami H, Okamoto I, Arao T et al. MET amplification as a potential therapeutic target in gastric cancer. Oncotarget 2013; 4: 9-17.
20. McDermott U, Sharma SV, Dowell L et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 2007; 104: 19936-41.
21. Nakagawa T, Tohyama O, Yamaguchi A et al. E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci 2010; 101: 210-5.
22. Okamoto W, Okamoto I, Arao T et al. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther 2012; 11: 1557-64.
23. Okamoto W, Okamoto I, Yoshida T et al. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition. Mol Cancer Ther 2010; 9: 1188-97.
24. Smolen GA, Sordella R, Muir B et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006; 103: 2316-21.
25. Kunii K, Davis L, Gorenstein J et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008; 68: 2340-8.
26. Nakamura K, Yashiro M, Matsuoka T et al. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology 2006; 131: 1530-41.
27. Yashiro M, Shinto O, Nakamura K et al. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int J Cancer 2010; 126: 1004-16.
28. Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 1998; 78: 1143-53.
29. Nessling M, Solinas-Toldo S, Wilgenbus KK, Borchard F, Lichter P. Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2. Genes Chromosom Cancer 1998; 23: 307-16.
30. Sakakura C, Mori T, Sakabe T et al. Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosom Cancer 1999; 24: 299-305.
31. Yanagihara K, Seyama T, Tsumuraya M, Kamada N, Yokoro K. Establishment and characterization of human signet ring cell gastric carcinoma cell lines with amplification of the c-myc oncogene. Cancer Res 1991; 51: 381-6.
32. Yanagihara K, Takigahira M, Takeshita F et al. A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination. Cancer Res 2006; 66: 7532-9.
33. Yanagihara K, Takigahira M, Tanaka H et al. Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer. Cancer Sci 2005; 96: 323-32.
34. Yanagihara K, Tanaka H, Takigahira M et al. Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice. Cancer Sci 2004; 95: 575-82.
35. Yamaguchi H, Yoshida S, Muroi E et al. Phosphoinositide 3-kinase signaling pathway mediated by p110alpha regulates invadopodia formation. J Cell Biol 2011; 193: 1275-88.
36. Ueda T, Sasaki H, Kuwahara Y et al. Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. Cancer Res 1999; 59: 6080-6.
37. Catenacci DV, Henderson L, Xiao SY et al. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov 2011; 1: 573-9.
38. Humar B, Fukuzawa R, Blair V et al. Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Res 2007; 67: 2480-9.
39. Hagiwara A, Takahashi T, Sawai K et al. Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res 1993; 53: 687-92.
40. Guarino M. Src signaling in cancer invasion. J Cell Physiol 2010; 223: 14-26.